Comparison of tofogliflozin 20 mg and ipragliflozin 50 mg used together with insulin glargine 300 U/mL using continuous glucose monitoring (CGM): A randomized crossover study

Endocrine journal

Soichi Takeishi¹  Shodo Takekoshi¹  Hiroki Tsuboi¹ 

[1] Department of Diabetes, General Inuyama Chuo Hospital, Inuyama 484-8511, Japan

关键词: Tofogliflozin;    Insulin glargine 300 U/mL;    Continuous glucose monitoring;   

DOI  :  10.1507/endocrj.EJ17-0206

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

To investigate whether sodium glucose co-transporter 2 inhibitors (SGLT2i), tofogliflozin or ipragliflozin, achieve optimal glycemic variability, when used together with insulin glargine 300 U/mL (Glargine 300).Thirty patients with type 2 diabetes were randomly allocated to 2 groups.For the first group After admission, tofogliflozin 20 mg was administered; Fasting plasma glucose (FPG) levels were titrated using an algorithm and stabilized at 80 mg/dL level with Glargine 300 for 5 days; Next, glucose levels were continuously monitored for 2 days using continuous glucose monitoring (CGM); Tofogliflozin was then washed out over 5 days; Subsequently, ipragliflozin 50 mg was administered; FPG levels were titrated using the same algorithm and stabilized at 80 mg/dL level with Glargine 300 for 5 days; Next, glucose levels were continuously monitored for 2 days using CGM.For the second group, ipragliflozin was administered prior to tofogliflozin, and the same regimen was maintained.Glargine 300 and SGLT2i were administered at 800 AM.Data collected on the second day of measurement (mean amplitude of glycemic excursion [MAGE], average daily risk range [ADRR]; on all days of measurement) were analyzed.Area over the glucose curve (<70 mg/dL; 000 to 600, 24-h), M value, standard deviation, MAGE, ADRR, and mean glucose levels (24-h, 800 to 2400) were significantly lower in patients on tofogliflozin than in those on ipragliflozin.Tofogliflozin, which reduces glycemic variability by preventing nocturnal hypoglycemia and decreasing postprandial glucose levels, is an ideal SGLT2i when used together with Glargine 300 during basal insulin therapy.

【 授权许可】

Unknown